Biocon Ltd (BIOCON)
₹351.80
Mkt cap
₹57,333 Cr
P/E ratio
78.80
P/B
1.68
Div yield
0.14%
ROE
1.40%
ROCE
3.61%
EPS (TTM)
₹4.46
Book value
₹210
52W range
318–447
Sector
Healthcare
Price history
Previous close
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
NSE BIOCONBSE 532523
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsBearish
52-week range
−21.32% from high₹352
₹318+10.49% from low₹447
Current
₹351.80
Prev close
₹351.90
Day
−0.03%
Price performance
1D
−0.03%
1W
+8.75%
1M
−6.68%
3M
−17.29%
6M
−2.88%
1Y
−2.90%
YTD
−10.47%
Financials
Revenue, profit & margin
P/E ratio
78.8×
BIOCON is 129% above the sector median of 34.4×
BIOCON78.8×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 | |
| Expenses | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 | |
| Operating Profit | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 | |
| OPM % | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% | 20% | 23% | 20% | |
| Other Income | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 | |
| Interest | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 | |
| Depreciation | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 | |
| Profit before tax | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 | |
| Tax % | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% | -24% | 20% | -7% | |
| Net Profit | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 | |
| EPS in Rs | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | 0.87 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.70% · closed higher next day 20 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23◦ | 9 Feb '24◦ | 16 May '24◦ | 9 Aug '24 | 30 Oct '24◦ | 31 Jan '25 | 8 May '25◦ | 7 Aug '25◦ | 11 Nov '25◦ | 12 Feb '26◦ | 7 May '26 | 5 Aug '26◦ |
| Earnings day | −0.02% | −2.45% | +0.03% | −0.65% | −1.43% | +1.55% | −1.40% | −5.72% | +5.40% | +0.77% | −0.48% | +2.68% |
| +1 day | +0.75% | −2.27% | −0.39% | −0.38% | −3.06% | +3.77% | −1.93% | −6.07% | +8.28% | +1.41% | +2.15% | +0.27% |
| +5 days | +2.77% | +6.46% | +4.48% | +1.67% | +0.19% | +11.19% | +1.43% | +0.03% | +6.49% | +2.37% | +12.52% | −1.22% |
| +15 days | +5.72% | +2.01% | +9.89% | +7.15% | +9.96% | −5.88% | +0.37% | −2.22% | +6.47% | +3.91% | +11.35% | −1.60% |
| +30 days | +8.77% | −6.14% | +16.97% | +9.20% | +9.43% | −6.65% | +5.01% | −1.29% | +3.44% | −2.63% | +10.16% | −9.45% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Re 0.50 Per Share | — | 3 Jul '26 | 3 Jul '26 |
Shareholding
as of Sep 202644.68%Promoter
Promoters44.68%
FIIs8.64%0.50
DIIs29.22%5.89
Public17.20%6.55
Government0.08%0.03
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Biocon | ₹351.80 | 78.83 | 57,333 | 0.14% | 137 | +327.65% | 4,336 | +10.00% | 3.61% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts112
TranscriptAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026PPTDec 2025PPTDec 2025TranscriptDec 2025PPTDec 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Biocon ranked No. 13 in Science magazine’s 2026 top global biotech and pharma employers list.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Oct - Board meeting on Nov 4, 2026 to approve Q2 FY27 results; earnings call scheduled same day.Board Meeting Intimation for To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2026 26 Oct - Biocon board meets Nov 4, 2026 to approve Q2 FY27 results; trading window closed till Nov 6.Company Statement 26 Oct - Biocon secures Yesintek market entry in nine additional countries, effective immediately.Company Statement 14 Oct - Biocon settles with Genentech, enabling Pebrilzo launch in EU/UK Q1 2027 and U.S. Q3 2028.